Complement inactivating proteins and intraspecies venom variation in Crotalus oreganus helleri.

Complement inactivating proteins and intraspecies venom variation in Crotalus oreganus helleri. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Complement inactivating proteins and intraspecies venom variation in Crotalus oreganus helleri. Abstract Text:

Jennifer D Jurado,Eppie D Rael,Carl S Lieb,Ernesto Nakayasu,William K Hayes,Sean P Bush,Jeremy A Ross,

Complement inactivating properties were detected in venom from the southern California distribution of Crotalus oreganus helleri (Southern Pacific Rattlesnake). This activity showed strong geographic bias to the San Bernardino Mountain range, and venom from this area reacted strongly with Fraction 5 antiserum (AF5). However, venoms from the San Jacinto Mountain range, which have been previously shown to contain Mojave toxin, did not inhibit complement and did not react with AF5. AF5 has been previously shown to recognize a protease in C. scutulatus venom that inactivates complement, but the identity of this protein has remained unknown. Using a functional venomic approach, utilizing two-dimensional gel electrophoresis coupled with liquid chromatography and tandem mass spectrometry (LC/MS/MS), we have identified catrocollastatin and hemorrhagic toxin II (HT-2) as the primary proteins recognized by AF5. The information we present within this manuscript further illustrates the now well-known reality of intraspecies venom variation and the challenges faced in providing comprehensive polyvalent antivenoms.

Complement inactivating proteins and intraspecies venom variation in Crotalus oreganus helleri. Publishing Authors By Initials

JD Jurado,ED Rael,CS Lieb,E Nakayasu,WK Hayes,SP Bush,JA Ross,

For similar investigative techniques: chemistry, analytical: mass spectrometry: tandem mass spectrometry research abstracts see: investigative techniques: chemistry, analytical: mass spectrometry: tandem mass spectrometry research

PUBMED ID PMID:

MEDLINE DATE:

Complement inactivating proteins and intraspecies venom variation in Crotalus oreganus helleri. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Toxicon : official journal of the International So

VOLUME: 49

Page Numbers: 339-50

Journal Abbreviation: Toxicon

ISSN: 0041-0101

DAY: 25

MONTH: 10

YEAR: 2006

Complement inactivating proteins and intraspecies venom variation in Crotalus oreganus helleri. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 1307333

Complement inactivating proteins and intraspecies venom variation in Crotalus oreganus helleri. Keywords Mesh Terms:

KEYWORDS: Tandem Mass Spectrometry

MESH TERMS: pharmacology

Chemical & Substance for Abstract: Complement inactivating proteins and intraspecies venom variation in Crotalus oreganus helleri. Information

Substance Name: catrocollastatin

Registry Number: EC 3.4.24.-

Grant and Affiliation Information for Complement inactivating proteins and intraspecies venom variation in Crotalus oreganus helleri.

AFFILIATION: Department of Biological Sciences, University of Texas at El Paso, El Paso, TX 79902, USA.

Country: England

AGENCY: United States NCRR

GRANT: 5G12RR008124

ACRONYM: RR

MEDLINETA: Toxicon

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Complement inactivating proteins and intraspecies venom variation in Crotalus oreganus helleri Related Publications

• A minimum CR2 binding domain of C3d enhances immunity following vaccination.
• Attitudes of genetic counselors towards expanding newborn screening and offering predictive genetic testing to children.
• Benjamin M. Baker, JR.: 1901-2003.
• Birth characteristics, maternal reproductive history, and the risk of infant leukemia: a report from the Children's Oncology Group.
• Carnitine as a possible adjunct in parenteral feeding.
• Chronic vitamin A status and acute repletion with retinyl palmitate are determinants of the distribution and catabolism of all-trans-retinoic acid in rats.
• Circadian rhythms play role in cancer research.
• Complement inactivating proteins and intraspecies venom variation in Crotalus oreganus helleri.
• Differences in cyclin D2 and D1 protein expression distinguish forebrain progenitor subsets.
• Diffusion imaging: insight to cell status and cytoarchitecture.
• Failure of embryos from bluetongue infected cattle to transmit virus to susceptible recipients or their offspring.
• Gestational programming of offspring obesity/hypertension.
• Kinetics of glial glutamine efflux and the mechanism of neuronal uptake studied in vivo in mildly hyperammonemic rat brain.
• Language use in females with fragile X or Turner syndrome during brief initial social interactions.
• Lentivirus-like particles without reverse transcriptase elicit efficient immune responses.
• Maternal hemoglobin concentration during pregnancy and risk of infant leukaemia: a children's oncology group study.
• More to the E-Ferol case than presented.
• Neurologic Manifestations
  of HIV Infection Without AIDS:Follow-UP of a Cohort
  of Homosexual and Bisexual Men.
• Penicillin; applied pharmacology.
• Phosphorylation-regulated inhibition of the Gz GTPase-activating protein activity of RGS proteins by synapsin I.
• Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy.
• Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance.
• Random activation energy model and disordered kinetics, from static to dynamic disorder.
• Reduction of anti-HIV-1 Gag immune responses during co-immunization: immune interference by the HIV-1 envelope.
• Species differences in the in vitro metabolism of deltamethrin and esfenvalerate: differential oxidative and hydrolytic metabolism by humans and rats.
• The effect of lactation length on the circulating concentrations of progesterone and oestradiol in the early weaned sow.
• Transoral surgery: an anatomic study.
• Use of modified pericranial flaps in anterior skull base reconstruction: technical note.
• Vascular targeted nanoparticles for imaging and treatment of brain tumors.
• Virus-like particles: designing an effective AIDS vaccine.